ClinicalTrials.gg
Status unknownNCT04126850Updated Oct 17, 2019

Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

An observational study in Autoimmune Uveitis, Behçet Disease and Vogt-Koyanagi-Harada Disease, sponsored by Fakultas Kedokteran Universitas Indonesia. Status unknown at 1 site in Indonesia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-17.

Sponsored by Fakultas Kedokteran Universitas Indonesia · Observational

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

Read the detailed description

Gut microbiome has been widely studied around the globe, and it is convinced that the gut microbiome plays an essential role in many human diseases. In a published review showed the presence of microbes in blood from a patient who suffered from non-communicable disease. The microbes present in dormant or not-immediately-culturable states as if blood is a 'sterile' environment. It was argued that the difficulty of culturing microbes from the blood was coming from the limited understanding of suitable growth/isolation media for the microbes to be cultured. This limitation can be overcome by the sequenced-based methods for detecting non-proliferating microbes. The presence of microbes in blood also can be observed by ultrastructural (microscopic) methods. Through the microscopic observations, it was witnessing the presence of coccus and bacillus shaped bacteria that present proximity to (Red Blood Cell) RBCs in sample blood patients with Alzheimer's or Parkinson's Disease. The presence of microbes in the places other than their normal location state by term 'atopobiosis'. The presence of microbes in blood suspected as a result of translocation between the gut to the blood.

Therefore, according to the current knowledge of microbiome association and the human diseases, we are eager to conduct a pilot project that gives a comprehensive picture of the association between the microbiome and uveitis disease partially non-infectious and idiopathic uveitis. We will investigate microbiome profiling in the intestinal and extra-intestinal of uveitis patients before and after treatment to see whether any alteration of microbial abundance at two distinct clinical conditions partially in uveitis patients with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis. Another objective of this study is to explore any pathogenic microorganism that present in uveitis patients samples conducted by a sequenced-based method.

02

Conditions studied

  • Autoimmune Uveitis
  • Behçet Disease
  • Vogt-Koyanagi-Harada Disease
  • Idiopathic Uveitis
  • Noninfectious Panuveitis
  • Anterior Uveitis Idiopathic
  • Posterior Uveitis
  • Intermediate Uveitis

Keywords

  • Microbiome
  • Autoimmune Uveitis
  • Vogt-Koyanagi-Harada Disease
  • Behçet Disease
  • Idiopathic Uveitis
  • Metatranscriptomic
  • Amplicon
03

In context

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

This study's planned enrollment of 10 is below the median of 90 across 63 observational studies indexed under Behcet Syndrome.

Browse Behcet Syndrome studies →

Lead sponsor

Fakultas Kedokteran Universitas Indonesia is the lead sponsor of 36 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Non-infectious and idiopathic uveitis patients registered from November 2019 at Cipto Mangunkusumo Hospital, Indonesia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New patient registered at Cipto Mangunkusumo Hospital since November 2019
  • Patient diagnosed with non-infectious uveitis (with Behcet, VKH history)
  • Patient idiopathic uveitis (proven to have negative result by available etiological uveitis work-ups)
  • Minimum age: 18 years old
  • Experience active inflammation in the past 180 days and or during patient registration following Standard Uveitis Nomenclature (SUN) guidelines, in at least:

    • equal and or more than 2+ anterior chamber cells
    • equal and or more than 2+ vitreous haze and/or
    • active retinal/choroidal lesions

Exclusion criteria

Exclusion Criteria:

  • patients had taken probiotics supplement or antibiotics 3 months before sample collection
  • or who experience prolonged diarrhea or constipation
  • or undergone gastrointestinal surgery
  • having any form of
  • having a systemic disease such as hypertension, obesity, inflammatory bowel disease, or diabetes.
  • Disagree to sign
  • Uveitis is proven to be an infectious origin
  • Pregnant patient
  • Loss to follow up patient

Healthy volunteers are recruited for this study after giving consent with the following inclusion criteria:

  • age: 18-50 years old (Man/Woman)
  • having no health complaints or symptoms
  • not in any long term medications
  • having no history of allergy
  • willing to cooperate in the study
  • state of complete physical, mental and social well being
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Differential abundant taxonomic groups bacterial

    The primer used in this amplicon study is targeted to 16S rRNA gene region V3-V4 to detect bacterial diversity in the samples. The sequencing will be generated by Illumina according to standard protocol. Prior filter is conducted using Prinseq-lite, then chimeric sequences remove using Usearch61 and left over the high quality reads. The (operational taxonomic unit) OTU is picked using bioinformatic tool (Quantitative Insights Into Microbial Ecology - QIIME). Taxonomic classification for de novo OTUs clustering will be generated using open source software package for bioinformatics data processing. Shanon diversity, Simpson index will be examined for calculating alpha diversity. And then we will do identification of differential abundant taxonomic groups. And do analysis correlation network between bacterial genera among two clinical condition (before and after received oral steroid) relatively to health control.

    Time frame: 0, 6 weeks

Secondary outcomes

  1. Detection pathogenic microorganism in samples

    In this study we are going to use IDseq Portal, a novel bioinformatics platform that designed for detection of microbes from metagenomic data. This analysis will be applied in all types samples (stool, blood, and aqueous humor). We expect to find any specific microbiome (bacterial/fungal/virus) signature in samples patient uveitis.

    Time frame: 0, 6 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2019; primary completion for Jul 2020, 8 months later.

Of 21 observational studies under Behcet Syndrome, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 81. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartEst.
Nov 1, 2019
Primary completionEst.
Jul 30, 2020
CompletionEst.
Jul 30, 2020
Last update
Oct 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04126850
Lead sponsor
Fakultas Kedokteran Universitas Indonesia
Responsible party
Ratna Sitompul (Prof. Dr. dr. Ratna Sitompul, SpM(K), Fakultas Kedokteran Universitas Indonesia) — Principal investigator
First posted
Oct 15, 2019
Start date
Nov 1, 2019 (estimated)
Primary completion
Jul 30, 2020 (estimated)
Completion
Jul 30, 2020 (estimated)
Last update
Oct 17, 2019

Study contacts

Ratna Sitompul, Professor
Contact
ratna_sitompul@yahoo.com
+628118009911
Rina La Distia Nora, PhD
Contact
rina.ladistia@ui.ac.id
+62811198910
Ratna Sitompul, Professor
principal investigator · RSUPN dr. Cipto Mangunkusumo Hospital (RSCM)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion